COVID-19 Detection Test in Oncology (EVIDENCE)

Unicancer logo

Unicancer

Status

Completed

Conditions

Oncology

Study type

Observational

Funder types

Other

Identifiers

NCT04367870
UC-TRA-2002
2020-A01002-37 (Other Identifier)

Details and patient eligibility

About

EVIDENCE is a non interventional, French, multicenter study. Patients will be screened by local severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoassay in their oncology department (rapid diagnostic test (RDT) or enzyme-linked immunosorbent assay (ELISA)). In patients with positive local SARS-CoV-2 immunoassay, a centralized SARS-CoV-2 ELISA will be performed in order to double check the immune response of all patients considered immune by local immunoassay.

Full description

Patients with cancer are a high-risk group in the COVID-19 pandemic. They are already vulnerable to infection because of their underlying illness and often immunosuppressed status, and are at increased risk of developing severe complications from the virus, including intensive care unit admission or even death. In light of this increased risk, many guidelines have been issued, aiming at minimizing the risk of SARS-CoV-2 infection occurrence and/or gravity. These changes in cancer care could however translate in less efficient or delayed treatments. In this study, we want to detect cancer patients that were exposed to the SARS-CoV-2 virus and acquired an immunity. These patients immune to the SARS-CoV-2 virus are susceptible to receive the standard of care, meaning the most appropriate treatment to manage their cancer. Large-scale serodiagnosis are considered as the solution to progressively relax the current lockdown in France. RDT and ELISA, which were not available until mid-April 2020, will be largely used in the general French population over the coming months, millions of tests have already been ordered by French authorities and companies. The aim of this study is to control that oncology patients qualified immune by local immunoassay are indeed safe (i.e. have extremely low risk of SARS-CoV-2 infection following a positive local immunoassay test). Of note, several immunoassays (RDT or ELISA) will be used in the participating centers throughout the study. A confirmation of positive cases yielded by these different immunoassays will be performed by a centralized ELISA, in order to minimize the risk of false positive results.

Enrollment

441 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients ≥18 years old
  • Patient diagnosed with invasive cancer (solid tumor only)
  • Patient in active phase of cancer treatment (surgery, chemotherapy, radiotherapy, immunotherapy or targeted therapy ongoing or planned within the next month- excepted patient treated by hormonotherapy and targeted therapy alone in adjuvant setting)
  • Patient with a local immunoassay realized before inclusion realized during the standard practice with a positive or negative result (test name and reference should be available)
  • Information and non-opposition of the patient to the study procedure

Exclusion criteria

  • Person deprived of their liberty or under protective custody or guardianship
  • Patients unwilling or unable to comply with the medical follow-up required by the study because of geographic, familial, social, or psychological reasons
  • Patients treated for a hematological malignancy
  • Life expectancy <6 months

Trial design

441 participants in 2 patient groups

Non immune patient
Description:
Patients with a negative SARS-CoV-2 immunoassay
Immune patient
Description:
Patients with a positive SARS-CoV-2 immunoassay

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems